PharmAthene (PIP) sinking, down 15.1% premarket, as the FDA says it's put the firm's SparVax...


PharmAthene (PIP) sinking, down 15.1% premarket, as the FDA says it's put the firm's SparVax anthrax vaccine program on clinical hold. Details to come from the agency within 30 days, but no adverse effects have been reported as the trial hadn't yet begun.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs